Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies and Companion Diagnostics 2014

David Hoon's Biography



David Hoon, Director/Chief, John Wayne Cancer Institute

As Professor and Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dave S. B. Hoon M.Sc, Ph.D, interacts with external academic, industry, government agencies, and international cancer centers to develop innovative translational research opportunities. He has coauthored more than 300 peer-reviewed articles and reviews, primarily related to translational molecular oncology of human solid tumors, and has over 25 patents on his studies. As founding Director of the Department of Molecular Oncology, Dr. Hoon continues to pioneer investigations of RNA/genomic/epigenomic biomarkers for diagnostic, prognostic and predictive assessment of residual tumor cells. Dr. Hoon spearheads investigations of circulating DNA/miRNA biomarkers for staging cancer in patients enrolled in phase II/III clinical trials. Dr. Hoon’s team has developed diagnostic tissue biomarkers for molecular staging of sentinel lymph nodes and classification of human solid tumors such as melanoma, breast cancer and gastrointestinal cancer and brain tumors. In the last decade he and his team have designed and conducted biomarker companion studies as part of multicenter international phase II/III clinical trials. On the therapeutic front, Dr. Hoon is examining functional genomic and epigenomic changes as potential targets for development of novel approaches to treat or prevent malignancy. He also works on immunotherapeutics such as human monoclonal antibodies and immunogenetic responses to cancer immunotherapy.

David Hoon Image

New Approaches of Next Generation Sequencing of Circulating DNA in Cancer Patients

Monday, 27 October 2014 at 15:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Circulating-free DNA (cfDNA) has been shown to be useful blood cancer biomarkers over the last decade. cfDNA can be used to monitor tumor progression, tumor response to treatment, and early detection of tumor recurrence. cfDNA biomarkers can occur in different forms such as mutations, amplification, loss of heterozygosity(LOH), methylation, and size integrity. We have shown the clinical utility of all these blood biomarkers in various solid tumors. Over the past years different assay approaches have been employed to detect cfDNA such as PCR based assays. However the major issue has been developing clinical utility for health payer reimbursement.  More recently the utilization of Next Generation Sequencing (NGS) has taken the assessment of cfDNA to a higher level of accuracy and sensitivity. We have employed a novel digital NGS approach in collaboration with Guardant Health for ultra-sensitive detection of cfDNA in approximately 2 ml of serum of solid tumors. Studies were designed in solid tumors such as melanoma with paired tumor tissues and serum. NGS was performed at 1000x coverage of the entire panel of 60 genes which allowed accurate detection of mutations/deletions across the complete gene as opposed to single targeted regions of a gene. We demonstrated high correlation of cfDNA to respective tumors and association with clinical tumor progression. The assay is now CLIA lab approved.  Currently, we are validating the assay in multi-institute settings.


Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid Biopsies and Companion Diagnostics 2014Biofluid Biopsies and Companion Diagnostics 2014 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com